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Abstract  
Angiosarcomas are a rare group of tumours which have poor prognosis and limited treatment 
options. The development of new therapies has been hampered by a lack of good preclinical 
models. Here we describe the development of an autochthonous mouse model of angiosarcoma 
driven by loss of p53 in VE-cadherin expressing endothelial cells. Using Cdh5-Cre to drive 
recombination in adult endothelial cells, mice developed angiosarcomas with 100% penetrance 
upon homozygous deletion of Trp53 with a median lifespan of 325 days. In contrast, expression 
of the R172H mutant p53 resulted in formation of thymic lymphomas with a more rapid onset 
(median lifespan 151 days).  We also used Pdgfrb-Cre expressing mice which targets 
predominantly pericytes, as these have been reported as the cell of origin for a number of soft 
tissue sarcomas. Pdgfrb-Cre also results in low levels of recombination in venous blood 
endothelial cells in multiple tissues during development. Upon deletion of Trp53 in Pdgfrb-
Cre, Trp53fl/fl mice 65% developed lymphomas and 21% developed pleomorphic 
undifferentiated soft tissue sarcomas. None developed angiosarcomas. In contrast, 75% of 
Pdgfrb-Cre, Trp53R172H/R172H mice developed angiosarcomas with 60% of these mice also 
developing lymphomas. The median lifespan of the Pdgfrb-Cre, Trp53R172H/R172H mice was 151 
days. Re-implantation of angiosarcoma tumour fragments from Cdh5-Cre, Trp53fl/fl mice 
provided a more consistent and rapid model of angiosarcoma than the two spontaneous models. 
The ability to passage tumour fragments through the mouse provides a novel model which is 
amenable to preclinical studies and will help the development of potential new therapies for 
angiosarcoma. 
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Introduction  
 
 
Angiosarcomas are rare but aggressive endothelial cell tumours. Most arise spontaneously but 
they also develop following ionizing radiation and chronic lymphedema. They have a high risk 
of local recurrence and metastasis with limited treatment options such that the overall 5-year 
survival is around 35% [1]. They typically express endothelial markers such as CD31 and 
vascular endothelial growth factor (VEGF) and for this reason there is interest in the use of 
anti-angiogenic therapies for their treatment. Data from a number of clinical trials show 
promising activity of the VEGF-A monoclonal antibody bevacizumab and broad spectrum, 
small molecule tyrosine kinase inhibitors that target VEGF receptors [1]. However, the 
underlying pathways driving the pathogenesis of angiosarcoma are not well defined and 
together with the urgent need for effective therapies we set out to develop an autochthonous 
mouse model of angiosarcoma that could aid preclinical drug development efforts.  
 
Mutations in TP53 have been reported in human angiosarcomas with incidences of between 4 
and 52% reported in different studies [2-8]. In addition, mice with germline deletion of Trp53 
which are pre-disposed to development of lymphoma develop angiosarcomas in significant 
numbers [9,10]. The predominance and rapid development of lymphoma in these models 
precludes their usefulness as models of angiosarcoma. Attempts have therefore been made to 
overcome this by use of tissue specific Cre-Lox recombination of conditional alleles and 
alymphocytic mice [11,12]. 
 
There is increasing evidence that mesenchymal stem cells (MSCs) may be the cell of origin of 
a number of different sarcoma sub-types [13-18]. Coupled with the evidence that pericytes 
have been proposed as the identity of MSCs in normal tissues [19,20] and some sarcomas share 
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features of pericytes such as expression of NG2 and CD146 [21,22], we set out to address 
whether Pdgfrb-Cre and Cdh5-CreERT2 mice could be utilized to generate a model of 
angiosarcoma. Pdgfrb-Cre mice express Cre recombinase under the control of a fragment of 
the gene encoding platelet-derived growth factor receptor- (PDGFR-). This drives Cre 
mediated recombination in pericytes in a number of tissues [23,24] and low levels of 
recombination in venous blood endothelial cells in multiple tissues during development 
[25,26]. This allows us to target loss of p53 function to the pericyte lineage while also 
potentially targeting endothelial cell lineages. Cdh5-CreERT2 mice express Cre recombinase 
under the inducible control of the vascular endothelial cadherin (VE-cadherin; Cdh5) promoter 
in adult mice to drive expression in endothelial cells [27].  
 
It is widely accepted that mutant forms of p53 can exert dominant negative or gain-of-function 
effects that contribute to tumour development beyond that seen following loss of the wild type 
p53 protein alone [28,29]. Individuals with Li-Fraumeni syndrome carry inherited mutations 
in TP53 and are predisposed to tumour development including sarcomas. In mouse models of 
Li-Fraumeni syndrome expression of Trp53R172H, which corresponds to the TP53R175H hot 
spot mutation in human tumours, mice develop predominantly lymphomas but a small 
percentage also develop angiosarcomas [30,31]. We therefore generated mice in which 
Trp53R172H was expressed under the control of Pdgfrb-Cre and Cdh5-CreERT2 in addition to 
those carrying a floxed Trp53 allele.  
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Materials and Methods 
Animals 
Mice expressing Cre under the control of the Pdgfrb promoter (Pdgfrb-Cre) [23] or in the 
inducible control of the Cdh5 promotor (Cdh5-CreERT2) [27], were crossed to mice expressing 
either a mutant p53R172H [31] or floxed p53 allele [32] to give experimental cohorts on a 
mixed background segregating for C57BL/6J and S129 genomes. The mutant p53 allele is 
preceded by a STOP cassette, flanked by LoxP sites, such that upon activation of Cre 
recombinase the STOP cassette is excised and the mutant p53R172H expressed, while in the 
floxed p53 mice activation of Cre deletes exons 2-10 resulting in a loss of p53. Pdgfrb-Cre and 
Cdh5-CreERT2 mice were also crossed with Ai14 (Rosa-CAG-LSL-tdTomato-WPRE) mice 
[33], obtained from the Jackson Laboratory, to allow endogenous reporting in Pdgfrb and Cdh5 
expressing cells. Genotyping was carried out by Transnetyx (Cordova, TN). Cdh5-CreERT2 
mice were treated with tamoxifen (Sigma) (100 mg/kg, i.p.) for 5 days at 6 weeks of age. Mice 
were monitored twice weekly and sacrificed when cutaneous tumours had reached a maximum 
size of 1.5 cm or became sickly as defined by UK Home Office guidelines. Following sacrifice 
macroscopically identified tumours and major organs were removed and fixed in 10% neutral 
buffered formalin. In some instances, fresh samples were taken for generation of cell lines or 
tumour fragments taken for re-implantation. Animal studies and procedures were approved by 
the University of Edinburgh Ethical review committee (Application PL01-16) and conducted 
in accordance with United Kingdom Home Office regulations. 
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Histology and immunohistochemistry 
Formalin fixed tissues were routinely processed into paraffin wax blocks and sections cut for 
H&E staining and immunohistochemistry. Immunohistochemistry was carried out as 
previously described [34]. Primary antibodies used were CD31 at 1:800 (Abcam, ab28364), 
ERG (Dako, IR659), p53 at 1:2000 (Leica BioSystems, NCL-L-p53-CM5p), PDGFR at 1:100 
(CST, 3169S), and VE-cadherin at 1:4000 (Abcam, ab33168).  
 
Immunofluorescence 
Shaved dorsal skin was mounted on 3 mm blotting paper and placed in 4% methanol-free 
formaldehyde (Thermo-Fisher Scientific, 28906) at 4C for one hour. The skin was then 
washed with PBS and transferred to 18% sucrose overnight for cryoprotection prior to 
embedding in OCT embedding matrix (Cellpath, KMA-0100-00A) and frozen on dry ice. 7 
m cryotome sections were dried at room temperature in the dark for 30 minutes and washed 
in PBS containing 0.05% Tween 20 (Sigma Aldrich, P2287). To image endogenous tdTomato 
fluorescence, sections were incubated with 1 M DAPI for 10 minutes, washed twice with 
PBS, and mounted with Prolong Gold (Thermo-Fisher Scientific, P36930). For indirect 
immunofluorescence staining, sections were incubated with blocking buffer (PBS containing 
5% goat serum (Vector, S-1000) and 0.3% Triton X100 (Sigma Aldrich, T8787) for 30 
minutes, then incubated with primary antibodies PDGFR (1:25, Abcam Ab32570) or CD31 
(1:50, BD Pharmingen 550274) for 2 hours. Sections were then washed twice and incubated 
for 30 minutes with Alexafluor 488 conjugated secondary antibodies (Molecular Probes Inc - 
goat anti-rabbit 488 (A11034) or goat anti-rat 488 (A11006), washed twice, incubated with 
DAPI and mounted as described above. Images were obtained on a Zeiss LSM780 confocal 
microscope.  
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Cell culture 
Tumours from Pdgfrb-Cre, p53R172H/R172H mice were freshly processed by rinsing in PBS and 
then mincing to ~1 mm3 pieces using two scalpels. After transferring to a 15 ml Falcon tube 
containing 10 mL digestion media (maintenance medium omitting fetal bovine serum (FBS) 
and including 300 U/mL collagenase I (Worthington) and 100 U/mL hyaluronidase (Fisher), 
cells were subjected to shaking incubation at 37C for 18 hours. After pelleting at 1300 rpm 
for 5 minutes cells were resuspended in 2 mL maintenance media (DMEM/Ham’s F12 (Sigma), 
10% FBS (Gibco), amphotericin (Gibco) and penicillin-streptomycin (Sigma)) before being 
transferred to a six well plate. Cells were left undisturbed for 5-7 days in a humidified incubator 
at 37C with 5% CO2 before refreshing media and moving on to flasks when confluent. 
Tumours from Cdh5-CreERT2, Trp53fl/fl mice were manually minced using scalpels and left 
undisturbed for 5-7 days before transferring to flasks when confluent. Cells were maintained 
in Ham’s F-12K Medium (Gibco), 10% FBS (Gibco), amphotericin B (Gibco), penicillin-
streptomycin (Sigma), 0.1 mg/mL heparin (Sigma) plus 20 µg/mL endothelial cell growth 
supplement (Sigma, E2759) and checked routinely for mycoplasma infection.  
 
Western analysis 
SDS denatured protein samples made from RIPA lysates were run on 4-15% precast 
polyacrylamide gels (Biorad) in Tris/Glycine/SDS running buffer (Biorad) and transferred onto 
nitrocellulose using the Trans-Blot® Turbo System (Biorad). After blocking the membrane in 
5% BSA in PBS, anti-p53 antibody (VectorLabs, VP-P955) was added at 1:50 overnight at 
4C on a shaking platform. The membrane was washed in TBS-T thrice before being incubated 
with an HRP conjugated anti-rabbit secondary antibody (CST, #7074) at 1:1000). Washes were 
repeated and then the membrane visualized on a ChemiDoc (BioRad) using ECL western 
blotting substrate (Pierce). 
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 Gene expression profiling 
RNA prepared from angiosarcomas that developed in the Pdgfrb-Cre, p53R172H/R172H and Cdh5-
CreERT2, Trp53fl/fl mice was analyzed using the NanoString PanCancer Pathways panel 
(represents 750 cancer associated genes) on the NanoString nCounter DX platform as per the 
manufacturer’s instructions. For comparison Cdh5 positive liver endothelial cells were isolated 
from Ai14;Cdh5-CreERT2 mice 3 weeks following tamoxifen treatment [35]. A Cdh5 
(tdTomato) positive population of endothelial cells was collected using a BD FACSAria II. 
Following standard nCounter normalisation differentially expressed genes were identified 
using Student’s t-tests (p<0.05) between the angiosarcomas derived from the Pdgfrb-Cre, 
p53R172H/R172H and Cdh5-CreERT2, Trp53fl/fl mice and relative to the normal endothelial cells. 
Hierarchical cluster analysis was performed with the Cluster and Treeview programs [36]. 
Gene set enrichment analysis [37] was performed using the Phenotest R package. Gene 
ontology analysis was performed using the PANTHER classification system [38].     
 
Sub-cutaneous tumour growth 
Cell lines and tumour fragments derived from the mouse angiosarcomas were injected into both 
flanks of 6-8 week old female CD-1 nude mice (Charles River) and tumour growth measured 
twice weekly using calipers. Tumour volumes were calculated in Excel using the formula v = 
4/3r3. Animals were sacrificed when tumours reached the maximum size allowed and 
collected and fixed in 10% neutral buffered formalin. 
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 RESULTS 
 
Tumour development in Pdgfrb-Cre, Trp53R172H/R172H and Pdgfrb-Cre, 
Trp53fl/fl mice 
Experimental cohorts consisted of mice expressing either one (Pdgfrb-Cre, Trp53R172H/+) 
(n=16) or two (Pdgfrb-Cre, Trp53R172H/R172H) (n=28) mutant Trp53R172H alleles or loss of both 
Trp53 alleles (Pdgfrb-Cre, Trp53fl/fl) (n=14). The median lifespan of the Pdgfrb-Cre, 
Trp53R172H/R172H mice was 93 days compared to >365 days for the Pdgfrb-Cre, Trp53R172H/+ 
mice and 189.5 days for the Pdgfrb-Cre, Trp53fl/fl mice (Figure 1A). The deaths of all Pdgfrb-
Cre, Trp53R172H/R172H mice were due to tumour formation in contrast to the Pdgfrb-Cre, 
Trp53R172H/+ cohort where only 2/16 mice were culled due to tumour formation.  In the Pdgfrb-
Cre, Trp53fl/fl cohort 12/14 mice were culled due to tumour formation. Mice that were 
asymptomatic at 1 year of age were culled. 
 
Autopsy findings and tumour histology 
In the Pdgfrb-Cre, Trp53R172H/R172H cohort 75% (n=21/28) of the mice developed 
angiosarcomas. Of these 21 mice, 9 demonstrated only angiosarcomas whilst in the other 12 
mice lymphomas were also identified. The remaining Pdgfrb-Cre, Trp53R172H/R172H mice 
developed either lymphomas (n=5/28) or teratomas (n=2/28) (Figure 1B). Thus, the 
predominant tumour type was angiosarcoma with most mice developing multiple 
angiosarcomas in a number of different organs (Table 1) (Figure 1B: median 3, range 1-6 
tumours). No angiosarcomas were seen in the Pdgfrb-Cre, Trp53R172H/+ mice. The 2 Pdgfrb-
Cre, Trp53R172H/+ mice culled due to tumour formation had developed lymphomas. At autopsy, 
following culling of the asymptomatic Pdgfrb-Cre, Trp53R172H/+ mice at 1 year, 3 were found 
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to have developed lymphomas and 1 adenocarcinoma in the lung. The remainder showed no 
gross or histological abnormality (Figure 1C). Within the Pdgfrb-Cre, Trp53fl/fl mice 9 
developed lymphomas and 3 undifferentiated sarcomas upon histological examination, while 
the remaining 2 had no detectable tumour upon sacrifice (Figure 1D). 
 
Characterization of angiosarcomas in Pdgfrb-Cre, Trp53R172H/R172H mice 
The morphological appearances of the angiosarcomas were similar within and between mice. 
The tumours consisted of lobules of pleomorphic cells showing varying degrees of vascular 
formation typical of high-grade angiosarcomas (Figure 2A, B). Immunohistochemistry 
supported the morphological assessment with the tumour cells expressing CD31 and ERG 
(Figure 2C, D). There was no expression of CD34 by the tumour cells (not shown). The 
tumours also showed strong expression of p53 (Figure 2E) in keeping with the stabilization of 
mutant p53 that is often seen in human tumours expressing mutant p53. PDGFR-was 
expressed by stromal cells within the tumour masses but not reliably by the angiosarcomatous 
cells (Figure 2F). 
 
Development of undifferentiated sarcomas in Pdgfrb-Cre, Trp53fl/fl mice 
Three of the 14 (21%) Pdgfrb-Cre, Trp53fl/fl mice developed tumours with the morphological 
features of high-grade spindle cell and pleomorphic undifferentiated soft tissue sarcoma 
(Figure S1A). Immunohistochemistry showed no expression of p53 confirming the 
homozygous deletion of p53 in the Pdgfrb-Cre, Trp53fl/fl mice (Figure S1B) and strong 
expression of PDGFR-by the tumour cells (Figure S1C). Less than 10% of the cells expressed 
SMA in 2 of the cases whilst the other was completely negative for SMA. None of the tumour 
cells expressed CD31 (Figure S1D) or ERG (not shown).  
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PDGFR- Cre recombination does not occur in adult CD31 endothelial cells 
As the angiosarcomas that developed expressed CD31 but did not express PDGFR- we asked 
whether there was any Cre mediated recombination in CD31 positive endothelial cells in adult 
mice. Using Ai14 reporter mice (single-fluorescent reporter mice that express tdTomato after 
Cre-mediated recombination)[33] we found that Pdgfrb-Cre induced highly efficient 
recombination in mouse skin (Figure 3A), a tissue where a number of angiosarcomas arose in 
the Pdgfrb-Cre, Trp53R172H/R172H mice. To evaluate the specificity of recombination, we stained 
skin from Ai14;Pdgfrb-Cre mice for PDGFR-β and confirmed appropriate reporter expression 
by Pdgfrb-Cre (Figure 3B). Staining of Ai14;Pdgfrb-Cre mice skin for CD31 expression 
showed that recombination did not target adult endothelial cells and in some cases PDGFR- 
expressing cells were seen surrounding small CD31 positive endothelial cells (Figure 3C). This 
suggests that the angiosarcomas have arisen either from endothelial cell lineages that 
transiently express PDGFR- during development [25,26] or from other PDGFR- expressing 
pericyte lineages. Interestingly the undifferentiated sarcomas that developed in the Pdgfrb-Cre, 
Trp53fl/fl mice had retained expression of PDGFR- suggesting a different cell of origin. 
 
Tumour development in Cdh5-CreERT2, Trp53R172H/R172H and Cdh5-CreERT2, 
Trp53fl/fl mice 
To determine whether we could promote more efficient generation of angiosarcomas we 
directly induced expression of mutant p53 or loss of p53 in adult endothelial cells using Cdh5-
CreERT2 mice where Cre recombinase is driven by Cdh5, which encodes the endothelial 
specific VE-cadherin. Using Ai14;Cdh5-CreERT2 reporter mice we found that Cdh5-Cre 
induced recombination in CD31 positive endothelial cells (Figure S2). Experimental cohorts 
consisted of mice expressing either one (Cdh5-CreERT2, Trp53R172H/+) (n=15) or two (Cdh5-
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CreERT2, Trp53R172H/R172H) (n=8) mutant Trp53R172H alleles or loss of one (Cdh5-CreERT2, 
Trp53fl/+) (n=9) or both Trp53 alleles (Cdh5-CreERT2, Trp53fl/fl) (n=13). A control cohort of 
Cdh5-CreERT2 mice were also treated with tamoxifen (n=9). The median lifespan of Cdh5-
CreERT2, Trp53R172H/R172H mice was 151 days (range 109 - 198) (Figure 4A). In the Cdh5-
CreERT2, Trp53R172H/+ cohort 2/16 mice developed tumours and all others were asymptomatic 
mice and sacrificed at 1 year (Figure 4A, B). The median lifespan of Cdh5-CreERT2, Trp53fl/fl 
mice was 325 days (range 224 - 407) (Figure 4A). All were culled due to tumour formation. 
All Cdh5-CreERT2, Trp53fl/+ and Cdh5-CreERT2 mice were asymptomatic at 12 months of age 
and culled with no evidence of tumour formation upon autopsy.  
 
Autopsy findings and tumour histology 
In the Cdh5-CreERT2, Trp53R172H/R172H cohort 7/8 mice developed thymic lymphomas, with 
evidence of thymic hyperplasia in the remaining mouse, but none developed angiosarcomas 
(Figure 4B). Two of the mice that developed lymphomas also developed additional tumours: 
one an undifferentiated sarcoma and the other a hepatocellular carcinoma. In addition, one of 
the Cdh5-CreERT2 mice showed evidence of thymic hyperplasia with all the others showing no 
evidence of tumour formation upon autopsy (Figure 4B). In the Cdh5-CreERT2, Trp53R172H/+ 
mice two developed tumours: one a thymic lymphoma and the other an angiosarcoma (Figure 
4B).  At autopsy, following culling of the asymptomatic Cdh5-CreERT2, Trp53R172H/+ mice at 
1 year, the remainder showed no gross or histological abnormality. Thus, the predominant 
tumour type driven by Trp53R172H in the Cdh5-CreERT2 mice was lymphoma in contrast to the 
angiosarcomas that developed in the Pdgfrb-Cre, Trp53R172H/R172H mice. Within the Cdh5-
CreERT2, Trp53fl/fl cohort all mice developed angiosarcomas (13/13), many with multiple 
tumours which developed in a range of anatomical locations (Table 2) (Figure 4B). The Cdh5-
CreERT2, Trp53fl/+ mice had no detectable tumour upon sacrifice. When we looked at the 
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latency of the angiosarcomas and the lymphomas in all experimental mice we found that the 
lymphomas developed more rapidly than the angiosarcomas with a median survival of 163 
days (range 109 - 198) days and 325 days (range 224 - 407) respectively (Figure 4C). 
 
Characterization of angiosarcomas in Cdh5-CreERT2, Trp53fl/fl mice 
Many of the tumours were similar to those seen in the Pdgfrb-Cre, Trp53R172H/R172H mice 
comprising lobules of pleomorphic cells showing varying degrees of vascular formation 
(Figure 5A). However, many of the tumours showed extensive hemorrhage and necrosis. In 
some tumours a cavernous / telangiectatic pattern was evident with enlarged blood-filled spaces 
being lined by atypical endothelial cells. Immunohistochemistry supported the morphological 
assessment with the tumour cells expressing ERG, CD31 and VE-cadherin but not PDGFR 
(Figure 5). 12/13 tumours that developed in the Cdh5-CreERT2, Trp53fl/fl mice, did not express 
p53 (Figure 5F). The reason for p53 expression in the remaining angiosarcoma is not known. 
 
Comparison of gene expression profiles of Pdgfrb-Cre, Trp53R172H/R172H and 
Cdh5-CreERT2, Trp53fl/fl tumours 
To understand the differences between the angiosarcomas that developed in the Pdgfrb-Cre, 
Trp53R172H/R172H and the Cdh5-CreERT2, Trp53fl/fl mice we carried out gene expression analysis 
using the NanoString PanCancer Pathways panel. Tumour type specific gene expression 
profiles were determined by unsupervised hierarchical clustering with both tumour types also 
being significantly more different than normal Cdh5 derived endothelial cells (Figure 6A). 
Gene ontology analysis of the genes that were significantly differentially expressed between 
the two different angiosarcoma subsets showed that pathways linked to p53 and angiogenesis, 
including FGF and VEGF signalling pathways were over represented (Figure 6B). This 
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indicates that the gain of function Trp53R172H mutant drives expression of a different set of 
genes to those seen in the Cdh5-CreERT2, Trp53fl/fl mice, to initiate angiosarcoma development.  
 
To determine whether the differentially expressed genes gene changes seen in the mouse 
angiosarcomas reflect changes seen in human angiosarcomas we carried out gene set 
enrichment analysis of the differentially expressed genes in the mouse angiosarcomas 
compared to normal endothelial cells and compared this with published human data from a set 
of human angiosarcomas and normal endothelial cells (GSE4415: [39]). This showed a 
significant enrichment of genes associated with human angiosarcomas in the mouse tumours 
compared to those expressed in the normal endothelial cells (Figure 6C), indicating that the 
mouse angiosarcomas represent a sub-population of human angiosarcomas. Interestingly, 
analysis of genes associated with endothelial cell function showed that a number were 
significantly increased in angiosarcomas in both the human and mouse datasets (VEGFC, 
EPHA2), while others were differentially regulated in the human and mouse angiosarcomas 
(VEGF, VEGFB, KDR, MYC) (Figure 6D). 
 
Generation of cell lines and transplantation model 
We generated cell lines from 4 angiosarcomas that developed in the Pdgfrb-Cre, 
Trp53R172H/R172H and mice. As with the spontaneous tumours, the cell lines all expressed p53 
(Figure 7A) and genotyping showed that each cell line was homozygous for the R172H allele. 
Upon re-implantation of the cell lines into the flanks of mice two of the lines from the Pdgfrb-
Cre, Trp53R172H/R172H mice developed tumours, with morphological features of undifferentiated 
pleomorphic sarcomas (Figure 7Bi). Neither the generated cell lines nor the tumours retained 
expression of CD31 (Figure 7Bii). We also generated cell lines from four angiosarcomas that 
developed in the Cdh5-CreERT2, Trp53fl/fl mice. Genotyping confirmed that each cell line was 
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homozygous for the floxed Trp53 allele. However, none of the cell lines formed tumours when 
injected into the flanks of recipient mice. In an attempt to overcome the loss of endothelial 
markers upon culture of the angiosarcomas we implanted tumour fragments from three 
spontaneous angiosarcomas that developed in the Cdh5-CreERT2, Trp53fl/fl mice. All formed 
tumours and histological examination confirmed that these were angiosarcomas expressing 
both CD31 and ERG (Figure 7C, D). Furthermore, secondary implantation of frozen tumour 
fragments resulted in successful outgrowth of angiosarcomas in recipient wild type mice 
(Figure 7C, D).  
 
 
 
 
Discussion 
 
We have generated two mouse models of angiosarcoma driven by deregulation of p53. We 
used the Pdgfrb-Cre mouse that is known to target both pericytes and endothelial cells during 
development. This resulted in 75% of Pdgfrb-Cre, Trp53R172H/R172H mice developing 
angiosarcomas, which is higher than the 62% reported when Tie2-Cre mice were crossed to 
Trp53 floxed mice [11]. In this model p53 is deleted in both endothelium and the hematopoietic 
lineages. Interestingly we saw no angiosarcomas in the Pdgfrb-Cre, p53fl/fl mice suggesting 
that the Trp53R172H mutant is exerting a gain-of-function activity that is required for 
angiosarcoma development when Pdgfrb cells are targeted. The development of angiosarcomas 
in a small percentage of mice in a model of Li-Fraumeni syndrome that expresses Trp53R172H 
supports the specific involvement of mutant p53 in the development of angiosarcoma [30,31]. 
Analysis of Pdgfrb-Cre mice has shown that recombination occurs in a number of cell types 
during development including endothelial and mural cells [25,26] so it is not possible to define 
the cell of origin in the angiosarcomas that developed in the Pdgfrb-Cre, Trp53R172H/R172H mice. 
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 The cell of origin of sarcomas remains unclear although mounting evidence suggests that they 
are derived from mesenchymal cells [40]. NG2/CSPG4 is a cell surface proteoglycan expressed 
by pericytes, which are mesenchymal cells that surround blood vessels [41]. A recent study has 
shown that targeting p53 loss in adult mice using NG2/CSPG4 driven Cre recombination leads 
to the formation of bone and soft tissue sarcomas supporting the mesenchymal origin of these 
tumours [17]. In this study only one angiosarcoma developed indicating that they can arise 
from mesenchymal precursors but that the efficiency is much lower than that of other sarcoma 
types such as osteosarcomas and undifferentiated pleomorphic sarcomas that were the most 
frequent tumour types seen. Interestingly we found that loss of p53 in the Pdgfrb-Cre mice 
gave rise to undifferentiated sarcomas that expressed PDGFR-, albeit with a reduced 
efficiency and increased latency compared to that observed by Sato and colleagues. These 
differences may reflect differences in the efficiency of recombination in the Pdgfrb-Cre and 
Ng2/Cspg4-Cre mice or may be due to distinct pericyte subpopulations that are marked by 
PDGFR- and NG2 during development [42]. In the future, use of a conditional Pdgfrb-
iCreERT2 mouse [43] that allows specific deletion of Trp53 in the adult where Pdgfrb 
expression is restricted to pericytes, will allow further evaluation of the role of distinct 
mesenchymal cell lineages to the development of different sarcoma sub-types. 
 
To address whether direct targeting of adult endothelial cells would result in the development 
of angiosarcomas with higher efficiency we used the Cdh5-CreERT2 mouse. Surprisingly all 
Cdh5-CreERT2, Trp53R172H/R172H mice developed lymphomas. Studies in Cdh5-CreERT2 mice 
have reported recombination of a small (0.3%) subpopulation of bone marrow cells that are 
hematopoietic in nature [44]. Combined with the propensity of mutant p53 to drive 
lymphomagenesis this appears sufficient to drive development of lymphomas in the Cdh5-
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CreERT2, Trp53R172H/R172H mice. However, all of the Cdh5-CreERT2, Trp53fl/fl mice developed 
angiosarcomas with no lymphomas detected. The enrichment of genes associated with p53 in 
the differentially expressed genes between the tumours that develop in the two models indicates 
that, as expected, the gain of function Trp53R172H mutant drives expression of a different set 
of genes to those seen in the Cdh5-CreERT2, Trp53fl/fl mice, to initiate angiosarcoma 
development. Other mouse models targeting specific endothelial cell populations have also 
been reported. mTORC1 activation in endothelial cells following conditional deletion of its 
upstream inhibitor Tsc1 resulted in 100% of mice developing hepatic hemangiomas, and 
around 80% developing cutaneous lymphangiosarcomas [45]. This is in contrast to the 
aggressive angiosarcomas that developed upon direct targeting of Trp53 in endothelial cell 
lineages in the Cdh5-CreERT2, Trp53fl/fl mice. mTORC1 pathway activation has also been 
reported in human angiosarcomas [45,46] and has been linked to Myc-mediated transcriptional 
regulation of VEGF [45]; increased expression of both Myc and Vegfa in the angiosarcomas 
from the Cdh5-CreERT2, Trp53fl/fl mice suggest that a similar autocrine stimulation loop may 
be present in these tumours, although the involvement of mTORC signaling in these tumours 
is not known. Combined loss of Trp53, Pten and Ptpn12 also leads to the development of 
aggressive vascular lesions which was associated with both mTORC and MEK pathway 
activation suggesting that mTORC activation alone is not sufficient to drive aggressive 
angiosarcoma development [46]. In this study loss of Trp53 alone did not result in the 
development of angiosarcomas. However, the tumours arose from more restricted 
recombination in a sub-set of endothelial cells. Taken together with the distinctive spectrum of 
tumours seen upon deletion of Tsc1 this suggests that targeting distinct populations of 
endothelial cells in mice in combination with differential pathway activation impacts on the 
type and site of vascular tumour development. 
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Increased Myc expression downstream of the forkhead boxO (FoxO) pathway has been linked 
to endothelial cell proliferation and angiosarcoma development [48,49]. Interestingly, 
conditional triple knock-out of FOXO1, 3, 4 in mice results in development of thymic 
lymphomas and vascular lesions, predominantly haemangiomas, in a number of tissues with 
only 9% progressing to angiosarcomas, although there is no reported role for Myc in this model 
[38]. This is in contrast to the Cdh5-CreERT2, Trp53fl/fl mice where angiosarcomas arise 
predominantly in soft tissues as the vascular lesions that develop in the FOXO triple knock out 
mice are predominantly benign and arise in relation to the uterus and a number of other tissues 
[38]. FOXOs and p53 share many common target genes and may act in a cooperative manner 
in order to regulate gene transcription [50,51]. It will be interesting to establish whether the 
deregulation of such pathways is required for driving the transition from benign to malignant 
disease in the mouse models.  
 
Angiosarcomas in humans may be divided into several clinical groups. The majority of cases, 
around 50%, are cutaneous, breast parenchymal angiosarcomas account for around 14% of 
angiosarcomas, soft tissue 11%, heart 7% and bone 4% with a range of other sites accounting 
for the remainder [47]. Little is known of the factors that predispose to angiosarcoma 
development in the clinical setting and it may be that angiosarcomas constitute a range of 
interrelated clinical diseases with common endothelial features but different phenotypes and 
aetiologies. Comparison of gene expression profiles between the two mouse models and human 
angiosarcomas showed significant enrichment of angiosarcoma associated genes in the two 
models suggesting that the mouse models do represent some of the phenotypes present in the 
human disease. Use of these and other mouse models will help to unravel some of the targetable 
pathways in angiosarcoma. 
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Although genetically engineered models are used in preclinical studies, the long latency of 
tumour formation in the Cdh5-CreERT2, Trp53fl/fl mice (median lifespan 325 days) and the 
development of multiple tumours, would make therapeutic efficacy studies costly and 
challenging. Knock-out of p53 in alymphocytic Rag2−/−;Il2rg−/− mice leads to a high 
frequency of angiosarcomas (over 65%) with only sporadic formation of lymphomas. With a 
mean latency of 18 weeks this provides an alternative model that would be more amenable to 
therapeutic studies [12]. However, the lack of immune cell populations in these mice restricts 
their use for assessing immune modulators which are showing promise in sarcoma. A recent 
report has shown that use of a lentiviral vector-based system to introduce oncogenic HrasG12V 
in combination with loss of Cdkn2a via intravenous injection into immune competent mice 
resulted in the formation of angiosarcomas. These develop very rapidly and in multiple sites 
which is most likely influenced by the intravenous route of injection [40]. This provides a 
useful model for preclinical studies but the rapid development of multiple tumours will make 
these studies challenging.  
 
To overcome these issues, we generated cell lines from angiosarcomas that developed in the 
Pdgfrb-Cre, Trp53R172H/R172H and Cdh5-CreERT2, Trp53fl/fl mice in an attempt to generate 
syngeneic mouse models of angiosarcoma.  However, as has been reported previously [11], 
endothelial makers were rapidly lost when the tumours were established in culture, even when 
grown with endothelial cell specific supplements. In contrast, direct implantation of tumour 
fragments allowed us to establish angiosarcomas which could be frozen and passaged serially 
through wild type recipient mice. This had the benefit of reducing the latency of tumour 
formation while also restricting the number of tumours per mouse. Furthermore, the sub-
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cutaneous localization of the tumours allowed easy monitoring of tumour growth. We have 
used this transplantation approach previously to model HER2 breast cancer and have 
demonstrated its utility in determining drug efficacy and establishing models of drug resistance 
[34].  
 
Taken together our data indicate that deleting p53 in endothelial cells in the adult mouse is the 
most effective way to generate angiosarcomas. This resulted in 100% penetrance with no 
formation of lymphomas. The development of lymphomas in the Cdh5-CreERT2, 
Trp53R172H/R172H mice supports a strong selection for angiosarcoma formation following loss of 
p53 in contrast to expression of the gain-of-function mutant p53. This is supported by 
angiosarcoma formation in mice in which loss of Trp53 is combined with loss of Ptpn12 and 
Pten [41]. The further establishment of a transplantation model of angiosarcoma provides a 
novel approach for testing potential new therapeutics in this disease setting. 
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Figure 1. Tumour development in Pdgfrb-Cre mice. (A) Kaplan-Meier curves showing 
significant difference in survival between Trp53R172H/R172H (n=28), Trp53R172H/+ (n=16) and 
Trp53fl/fl (n=14) mice (log-rank p < 0.0001). (B) Tumour incidence and type in the different 
mouse cohorts. 
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Figure 2. Histology and immunohistochemistry of mouse angiosarcomas in Pdgfrb-Cre, 
Trp53R172H/R172H mice. (A, B) H&E staining showed vascular, lobulated tumour masses: scale 
bar = 500 m. These were composed of pleomorphic tumour cells showing variable 
vasoformative capability: scale bar = 50 m (B). (C-F) Immunohistochemical analysis with 
antibodies to (C) CD31: scale bar = 50 m; (D) ERG: scale bar = 250 m; (E) p53: scale bar 
= 250 m and (F) PDGFR-: scale bar = 50 m.  
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Figure 3. PDGFR does not co-localize with CD31 in mouse skin. Confocal micrographs of 
fixed frozen dorsal skin from the Pdgfrb-Cre mouse crossed with a tdTomato floxed reporter 
(Ai14;Pdgfrb-Cre) showing (A) tdTomato fluorescence (red) (B) PDGFR antibody staining 
(green) and (C) CD31 antibody staining (green). DAPI (blue) indicates nuclei. Arrow 
demonstrates a CD31 labeled endothelial cell surrounded by a tdTomato positive perivascular 
cell: scale bars = 50 m. 
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Figure 4. Tumour development in Cdh5-CreERT2 mice. (A) Kaplan-Meier curves showing 
significant difference in survival between different mouse cohorts (log-rank p < 0.0001). (B) 
Tumour incidence and type in the different mouse cohorts. (C) Kaplan-Meier curves showing 
significant difference in survival between mice developing angiosarcomas and lymphomas 
(log-rank p < 0.0001). 
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Figure 5. Histology of and immunohistochemistry of mouse angiosarcomas in Cdh5-CreERT2, 
Trp53fl/fl mice. (A) H&E staining showing atypical cells lining vascular channels: scale bar = 
50 m. (B–F) Immunohistochemical analysis using antibodies to (B) ERG; (C) CD31 and (D) 
VE-cadherin, (E) PDGFR and (F) p53. Scale bars = 100 m.  
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 Figure 6. Gene expression analysis demonstrates mouse angiosarcomas have common and 
distinct features, but largely resemble human angiosarcomas. (A) Unsupervised hierarchical 
clustering of the NanoString PanCancer Pathways panel demonstrated some variation between 
the mouse angiosarcomas, but are significantly more different than normal Cdh5 derived 
endothelial cells. (B) Analysis of PANTHER signalling pathways that were significantly 
differentially expressed between the two mouse angiosarcomas. (C) The 299 significantly 
differently expressed genes between the mouse angiosarcomas and normal Cdh5 derived 
endothelial cells were significantly enriched in human angiosarcomas compared to normal 
human endothelial cells. (D) Genes associated with endothelial cell function were significantly 
increased in angiosarcomas in both the human and mouse datasets (VEGFC, EPHA2), while 
others were significantly (*p<0.05, Wilcoxon rank-sum test) differentially regulated in the 
human and mouse angiosarcomas (VEGF, VEGFB, KDR and MYC).  
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Figure 7. Characterization of cell lines and fragment-derived tumours from mouse 
angiosarcomas. (A) Western blot analysis of p53 expression in 4 Pdgfrb-Cre, Trp53R172H/R172H 
angiosarcoma derived cell lines. KEP are a mouse mammary tumour cell line that is deficient 
in p53 due to homozygous expression of a floxed p53 allele [52]. GAPDH was used as a 
loading control. (B) The morphology of tumours developing following implantation of 
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angiosarcoma derived cell lines was that of undifferentiated pleomorphic sarcomas (i) H&E, 
scale bar = 50 m. ii) Immunohistochemical analysis using antibody to CD31. The tumour 
cells were negative for CD31 as was the implanted angiosarcoma derived cell line (inset). Scale 
bar = 50 m; inset 25 m. (C) Growth of tumour fragments taken from 3 different Cdh5-
CreERT2, Trp53fl/fl mice following sub-cutaneous transplantation into wild type mice. 1109_2 
is the secondary transplantation of fragments derived from tumour 1109_1. (D) H&E staining 
and immunohistochemistry of Cdh5-CreERT2, Trp53fl/fl fragment-derived tumours. Left hand 
panels spontaneous tumour, middle panel primary passage of tumour fragments, right hand 
panels secondary passage of tumour fragments. Scale bar = 50 m 
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Table 1: Incidence of angiosarcoma formation in Pdgfrb-Cre, p53R172H/R172H mice 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
Mouse 
ID 
Number Position 
24 3 Hip, shoulder, leg 
152 5 Abdomen, flank, knee, hip, shoulder,  
156 2 Mammary fat pad, leg 
187 3 Heart, intramuscular back, fat shoulder 
191 5 Shoulder, flank, mammary fat pad, abdomen, back 
193 4 Back, neck, flank, abdomen 
194 1 Mammary fat pad 
195 3 Heart, intramuscular leg, armpit 
196 3 Shoulder, back, neck 
197 1 Flank 
215 6 Shoulder, intramuscular abdomen, sub-cutaneous back (x2), 
preputial, peritoneum 
249 2 Sub-cutaneous back, soft tissue chest 
251 2 Muzzle, leg 
259 2 Leg, diaphragm. 
265 3 Diaphragm, heart, sub-cutaneous back 
283 2 Shoulder, mammary fat pad 
289 2 Leg, chest 
291 6 Leg, mid abdomen, lower abdomen, back, neck, mammary fat 
pad 
298 2 Mammary fat pad (x2) 
301 3 Peritoneum, chest, shoulder 
330 2 Stomach, heart 
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Table 2: Incidence of angiosarcoma formation in Cdh5-Cre, p53fl/fl mice 
 
Mouse ID  Number  Position  
181  5 Mediastinal, intrabdominal, genital  
208 1 Shoulder  
210 1 Intrabdominal  
211 2 Hip, intrabdominal  
214 2 Intrabdominal, mammary fat pad  
215 1 Mediastinal, intrabdominal, perirenal  
216 3 Genital, perirenal, mammary fat pad  
247 3 Intrabdominal, genital  
253 1 Genital  
254 6 Mediastinal, intrabdominal, mammary fat pad  
255 1 Shoulder  
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Figure S1. Immunohistochemistry of mouse undifferentiated sarcomas. (A) 
H&E staining showed tumours comprising spindle and pleomorphic 
cells without evidence of specific lineage differentiation histologically. 
Cells were (B) negative for p53, (C) positive for PDGRFb and (D) negative 
for CD31. Scale bars = 50 µm. 
Disease Models & Mechanisms: doi:10.1242/dmm.038612: Supplementary information
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Figure S2. Confocal micrographs of fixed frozen liver (A) and 
dorsal skin (B) from Cdh5-CreERT2 mouse crossed with a 
tdTomato floxed reporter (Ai14; Cdh5-CreERT2) showing cytosolic 
tdTomato fluorescence (red) and CD31 antibody cell surface staining 
(green). DAPI (blue) indicates nuclei.
A B
Disease Models & Mechanisms: doi:10.1242/dmm.038612: Supplementary information
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
